Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

This study is testing a combination of three cancer drugs — gemcitabine, docetaxel, and toripalimab (an immunotherapy) — as a first treatment before radiation for people with advanced nasopharyngeal cancer (a cancer in the back of the nose and throat) linked to the Epstein-Barr virus. **You may be eligible if...** - You have been diagnosed with locally advanced, EBV-positive nasopharyngeal cancer (specific stages T3-T4, or with lymph node involvement, but no distant spread) - You have never received treatment for this cancer before - You are 18 years or older - You are generally healthy enough to handle treatment (able to carry out light daily activities) - Your blood counts, liver, and kidney function are within acceptable ranges - You are willing to use birth control during treatment and for 4 months afterward **You may NOT be eligible if...** - You have already received chemotherapy or radiation for nasopharyngeal cancer - You have an active autoimmune disease or have had an organ transplant - You are pregnant or breastfeeding - You have had a heart attack or serious heart problem in the last 6 months - You have significant hearing loss that affects daily life - You have moderate or severe nerve damage in your hands or feet Talk to your doctor to see if this trial is right for you.